Fate therapeutics appoints mark plavsic, dvm, phd, rac as chief technical officer

San diego, june 15, 2021 (globe newswire) -- fate therapeutics, inc. (nasdaq: fate), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that mark plavsic, dvm, phd, rac has been appointed chief technical officer. dr. plavsic brings over 20 years of broad technical excellence in global biopharmaceutical operations, having led teams in the commercial-scale cgmp manufacture and distribution, as well as the clinical-stage process, assay, and formulation development, of complex biologics. as chief technical officer, mark will oversee the company's manufacturing, technical, and supply chain operations.
FATE Ratings Summary
FATE Quant Ranking